A New Histology-based Prognostic Index for Acute Myeloid leukemia: Preliminary results for the "AML Urayasu Classification "
Authors:
- Toru MitsumoriTMToru Mitsumori
- Hideaki NittaHNHideaki Nitta
- Haruko TakizawaHTHaruko Takizawa
- Hiroko Iizuka-HonmaHIHiroko Iizuka-Honma
- Chiho FuruyaCFChiho Furuya
- Maki FujishiroMFMaki Fujishiro
- Shigeki TomitaSTShigeki Tomita
- Akane HashizumeAHAkane Hashizume
- Tomohiro SawadaTSTomohiro Sawada
- Kazunori MiyakeKMKazunori Miyake
- Mitsuo OkuboMOMitsuo Okubo
- Yasunobu SekiguchiYSYasunobu Sekiguchi
Preprint
- 16 January 2025
- preprint
- Published by MDPI AG in Preprints.org
Abstract
Background: To elucidate the mechanisms of resistance to treatment in patients with acute myeloid leukemia (AML) except for M3 so as to devise ways to overcome them and improve the treatment outcomes. Methods: For this study, we randomly selected 35 patients with AML who had received combined cytarabine plus idarubicin treatment for new-onset AML at our hospital. Expressions of 23 treatment-resistance-related proteins in the biopsy specimens were evaluated by immunohistochemical staining using the corresponding antibodies, followed by retrospective analysis of the correlations between the expression of the resistance proteins and patient survival. Results: The following four proteins were identified as being particularly significant in relation to treatment resistance and patient prognosis. 1) p53, 2) Multidrug resistance-associated protein 1 (MRP1) (Idarubicin extracellular efflux pump) 3)Aldo-keto reductase family 1 member B10 (AKR1B10) (Idarubicin-inactivating enzyme), and 4)AKR1B1 (AKR1B10 competitiveKeywords
All Related Versions
This publication has 40 references indexed in Scilit:
- Targeting multidrug resistance-associated protein 1 (MRP1)-expressing cancers: Beyond pharmacological inhibitionDrug Resistance Updates, 2021
- Inhibition of AKR1B10-mediated metabolism of daunorubicin as a novel off-target effect for the Bcr-Abl tyrosine kinase inhibitor dasatinibBiochemical Pharmacology, 2021
- Aldo-keto reductase inhibitors increase the anticancer effects of tyrosine kinase inhibitors in chronic myelogenous leukemiaJournal of Pharmacological Sciences, 2021
- Programmed Cell Death Ligand 1 Expression Level and Prognostic Significance in Acute Myeloid LeukemiaIndian Journal of Hematology and Blood Transfusion, 2021
- Multidrug-related protein 1 (MRP1) polymorphisms rs129081, rs212090, and rs212091 predict survival in normal karyotype acute myeloid leukemiaAnnals of Hematology, 2020
- Targeting MCL-1 in hematologic malignancies: Rationale and progressBlood Reviews, 2020
- Potent and Highly Selective Aldo–Keto Reductase 1C3 (AKR1C3) Inhibitors Act as Chemotherapeutic Potentiators in Acute Myeloid Leukemia and T-Cell Acute Lymphoblastic LeukemiaJournal of Medicinal Chemistry, 2019
- Synthesis of Potent and Selective Inhibitors of Aldo-Keto Reductase 1B10 and Their Efficacy against Proliferation, Metastasis, and Cisplatin Resistance of Lung Cancer CellsJournal of Medicinal Chemistry, 2017
- Glucose-regulated proteins in cancer: molecular mechanisms and therapeutic potentialNature Reviews Cancer, 2014
- TNF? and the TNF receptor superfamily: Structure-function relationship(s)Microscopy Research and Technique, 2000